Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

Omnicell, Inc. (OMCL)

Compare
35.01
-0.34
(-0.96%)
At close: March 28 at 4:00:01 PM EDT
34.10
-0.91
(-2.60%)
Pre-Market: 4:02:02 AM EDT
Loading Chart for OMCL
  • Previous Close 35.35
  • Open 35.10
  • Bid 25.23 x 100
  • Ask 44.67 x 100
  • Day's Range 34.47 - 35.31
  • 52 Week Range 25.12 - 55.75
  • Volume 808,202
  • Avg. Volume 498,535
  • Market Cap (intraday) 1.637B
  • Beta (5Y Monthly) 0.85
  • PE Ratio (TTM) 129.67
  • EPS (TTM) 0.27
  • Earnings Date Apr 30, 2025 - May 5, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 51.00

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.

www.omnicell.com

3,670

Full Time Employees

December 31

Fiscal Year Ends

Recent News: OMCL

View More

Performance Overview: OMCL

Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

OMCL
21.36%
S&P 500 (^GSPC)
5.11%

1-Year Return

OMCL
19.77%
S&P 500 (^GSPC)
6.22%

3-Year Return

OMCL
73.15%
S&P 500 (^GSPC)
21.97%

5-Year Return

OMCL
38.42%
S&P 500 (^GSPC)
119.59%

Compare To: OMCL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: OMCL

View More

Valuation Measures

Annual
As of 3/28/2025
  • Market Cap

    1.64B

  • Enterprise Value

    1.64B

  • Trailing P/E

    129.67

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.46

  • Price/Book (mrq)

    1.32

  • Enterprise Value/Revenue

    1.47

  • Enterprise Value/EBITDA

    18.18

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.13%

  • Return on Assets (ttm)

    0.16%

  • Return on Equity (ttm)

    1.03%

  • Revenue (ttm)

    1.11B

  • Net Income Avi to Common (ttm)

    12.53M

  • Diluted EPS (ttm)

    0.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    369.2M

  • Total Debt/Equity (mrq)

    30.77%

  • Levered Free Cash Flow (ttm)

    146.87M

Research Analysis: OMCL

View More

Company Insights: OMCL

Research Reports: OMCL

View More

People Also Watch